Sinovac Biotech (SVA) director linked entity reports 10.78M-share stake on Form 3

Rhea-AI Filing Summary

SINOVAC BIOTECH LTD director Andrew Y. Yan filed an initial ownership report on Form 3. The filing shows indirect ownership of 10,780,820 common shares held by SAIF Partners IV L.P., an investment entity for which he serves as the ultimate general partner.

The filing states he may be deemed to beneficially own the shares held by SAIF Partners IV L.P. but explicitly disclaims beneficial ownership except to the extent of his pecuniary interest. This report records existing holdings and does not reflect a new buy or sell transaction.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Yan Andrew Y

(Last) (First) (Middle)

SUITE 1102, 11/F, FIVE PACIFIC PLACE

28 HENNESSY ROAD, WANCHAI

(Street)

HONG KONG

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SINOVAC BIOTECH LTD [ SVA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares, par value $0.001 per share	10,780,820	I	By SAIF Partners IV L.P.(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. a. The Reporting Person is a director and sole shareholder of SAIF IV GP Capital Ltd., which is the sole general partner of SAIF IV GP, L.P., the sole general partner of SAIF Partners IV L.P. b. The Reporting Person may be deemed to beneficially own all the common shares, par value $0.001 per share, of the Issuer held by SAIF Partners IV L.P. c. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes.

	/s/ Andrew Y. Yan	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the SINOVAC BIOTECH (SVA) Form 3 filing by Andrew Y. Yan show?

The Form 3 shows indirect ownership of 10,780,820 common shares of SINOVAC BIOTECH LTD held by SAIF Partners IV L.P.. It is an initial ownership report, not a record of a new share purchase or sale.

Are the SINOVAC BIOTECH (SVA) shares held directly by Andrew Y. Yan?

No, the shares are held indirectly through SAIF Partners IV L.P.. Andrew Y. Yan is the director and sole shareholder of the entities that control this partnership, so he may be deemed to beneficially own these shares through that structure.

How many SINOVAC BIOTECH (SVA) shares are reported in this Form 3?

The filing reports 10,780,820 common shares of SINOVAC BIOTECH LTD. These shares are owned by SAIF Partners IV L.P., and the position is reported as an indirect ownership interest associated with Andrew Y. Yan.

Does the SINOVAC BIOTECH (SVA) Form 3 indicate any recent insider buying or selling?

No, this Form 3 is an initial ownership report and does not record a new transaction. It simply discloses the existing indirect holdings of SINOVAC BIOTECH LTD shares through SAIF Partners IV L.P. associated with Andrew Y. Yan.

What ownership disclaimer does Andrew Y. Yan make in the SINOVAC BIOTECH (SVA) Form 3?

He disclaims beneficial ownership of the shares held by SAIF Partners IV L.P. except to the extent of his pecuniary interest. The filing states that including these shares does not constitute an admission of beneficial ownership for Section 16 or other purposes.

How is SAIF Partners IV L.P. related to Andrew Y. Yan in the SINOVAC BIOTECH (SVA) filing?

The filing explains that he is a director and sole shareholder of SAIF IV GP Capital Ltd., which controls SAIF IV GP, L.P., the general partner of SAIF Partners IV L.P.. This structure links him to the reported SINOVAC share holdings.